KeyBanc starts LivaNova at Overweight on estimate upside potential

KeyBanc analyst Brett Fishbin last night initiated coverage of LivaNova (LIVN) with an Overweight rating and $81 price target The firm believes the company is undergoing an “underappreciated performance inflection.” LivaNova has multiple sources of potential upside versus expectations, as its growth outlook through 2028 looks conservative, the analyst tells investors in a research note. KeyBanc sees a “credible pathway” for improved margins once the company leverages growth investments.